Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk myelodysplastic syndrome.

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

A key differentiator for Rytelo is that it can be used to treat patients with or without ring sideroblasts – blood cells with a characteristic circle of iron deposits around their nucleus.

The Martin Jädersten group is investigating biological and clinical aspects of acute myeloid leukemia (AML) and runs academic trials exploring novel treatment strategies. The team leader Martin ...